These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12376881)

  • 1. [Transplantation of myelinating cells as regenerative therapy for multiple sclerosis - experimental basis and present state of clinical studies].
    Stangel M
    Nervenarzt; 2002 Oct; 73(10):937-45. PubMed ID: 12376881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remyelination in demyelinating disease.
    Scolding NJ; Franklin RJ
    Baillieres Clin Neurol; 1997 Oct; 6(3):525-48. PubMed ID: 10101588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial precursor cell transplantation therapy for neurotrauma and multiple sclerosis.
    Kulbatski I; Mothe AJ; Parr AM; Kim H; Kang CE; Bozkurt G; Tator CH
    Prog Histochem Cytochem; 2008; 43(3):123-76. PubMed ID: 18706353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation stimulates remyelination in areas of chronic demyelination.
    Foote AK; Blakemore WF
    Brain; 2005 Mar; 128(Pt 3):528-39. PubMed ID: 15699059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remyelinating strategies for the treatment of multiple sclerosis.
    Stangel M; Hartung HP
    Prog Neurobiol; 2002 Dec; 68(5):361-76. PubMed ID: 12531235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why does remyelination fail in multiple sclerosis?
    Franklin RJ
    Nat Rev Neurosci; 2002 Sep; 3(9):705-14. PubMed ID: 12209119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders.
    Pluchino S; Martino G
    J Neurol Sci; 2005 Jun; 233(1-2):117-9. PubMed ID: 15896808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretory products of central nervous system glial cells induce Schwann cell proliferation and protect from cytokine-mediated death.
    Lisak RP; Bealmear B; Nedelkoska L; Benjamins JA
    J Neurosci Res; 2006 Jun; 83(8):1425-31. PubMed ID: 16583376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haplotype matching is not an essential requirement to achieve remyelination of demyelinating CNS lesions.
    Tepavcević V; Blakemore WF
    Glia; 2006 Dec; 54(8):880-90. PubMed ID: 17006890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Candidate cells for remyelinating of the central nervous system].
    Nait Oumesmar B; Lachapelle F; Decker L; Avellana-Adalid V; Vitry S; Baron-Van Evercooren A
    Rev Neurol (Paris); 1998 Sep; 154(8-9):592-9. PubMed ID: 9809374
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhancing central nervous system remyelination in multiple sclerosis.
    Dubois-Dalcq M; Ffrench-Constant C; Franklin RJ
    Neuron; 2005 Oct; 48(1):9-12. PubMed ID: 16202704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular remyelinating therapy in multiple sclerosis.
    Yang J; Rostami A; Zhang GX
    J Neurol Sci; 2009 Jan; 276(1-2):1-5. PubMed ID: 18814888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplanted neural stem/progenitor cells generate myelinating oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination.
    Mothe AJ; Tator CH
    Exp Neurol; 2008 Sep; 213(1):176-90. PubMed ID: 18586031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repair of myelin disease: strategies and progress in animal models.
    Duncan ID; Grever WE; Zhang SC
    Mol Med Today; 1997 Dec; 3(12):554-61. PubMed ID: 9449127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous remyelination is induced by transplant rejection in a viral model of multiple sclerosis.
    Hatch MN; Schaumburg CS; Lane TE; Keirstead HS
    J Neuroimmunol; 2009 Jul; 212(1-2):74-81. PubMed ID: 19477025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies in multiple sclerosis. II. Long-term repair.
    Scolding N
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1711-20. PubMed ID: 10603622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using stem cells in multiple sclerosis therapies.
    Muraro PA; Cassiani-Ingoni R; Martin R
    Cytotherapy; 2004; 6(6):615-20. PubMed ID: 15764028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schwann cells genetically engineered to express PSA show enhanced migratory potential without impairment of their myelinating ability in vitro.
    Lavdas AA; Franceschini I; Dubois-Dalcq M; Matsas R
    Glia; 2006 Jun; 53(8):868-78. PubMed ID: 16598779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell and progenitor cell transplantation in multiple sclerosis: the discrepancy between neurobiological attraction and clinical feasibility.
    Lassmann H
    J Neurol Sci; 2005 Jun; 233(1-2):83-6. PubMed ID: 15949497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurotrophin receptor p75NTR in Schwann cells is implicated in remyelination and motor recovery after peripheral nerve injury.
    Tomita K; Kubo T; Matsuda K; Fujiwara T; Yano K; Winograd JM; Tohyama M; Hosokawa K
    Glia; 2007 Aug; 55(11):1199-208. PubMed ID: 17600367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.